Connect with us

Media & Technology

Fernhill Corp (OTCMKTS: FERN) Blue Sky Breakout as Emerging Crypto Player Acquires PerfectMine & Signs LOI to Acquire Digital Asset Crypto Trading Platform

Published

on

Fernhill Corp (OTCMKTS: FERN) continues to move northbound with power in recent trading quickly emerging as an investors favorite and major volume leader regularly topping $5 million in daily trading volume. Microcapdaily first reported on FERN back on July 23 when FERN was in the $0.02 range stating at the time: “FERN is getting noticed by some pretty heavy hitter penny stock players.  FERN took off in May after the Company reported it had upgraded its listing on OTCMarkets to Pink Current Status and hired senior technology M&A and corporate finance executive, Chris Kern, who has over 25 years of hands-on experience and facilitated over $750 million in transactions. FERN has an outstanding looking balance sheet with just $350k in total liabilities. The Company recently announced it is nearing completion of its due diligence on a targeted acquisition in the Cryptocurrency and Blockchain industry signing an LOI to acquire a SaaS based algorithmic crypto mining operating system platform for crypto mining pools and enthusiasts.  

Since than FERN acquired PerfectMine, a fully operational turn-key platform that provides optimized operating systems for a wide variety of GPU and CPU mining rigs to improve efficiency as well as remotely monitor and manage them. The Company has also signed an LOI to acquire a groundbreaking digital asset crypto trading platform. One of the most compelling features of the target’s technology is that it is directly integrated with over 25 different leading crypto currency exchanges to provide the best execution price for any crypto trading pair, providing seamless liquidity on a global scale. In short, this platform bridges the gap between crypto currencies and the more traditional trading platforms. FERN is trading like a winner with strong new support at every new price level as it continues on a blue sky breakout. 

Fernhill Corp (OTCMKTS: FERN) is a diversified technology holding company that has interests in and seeks to acquire, build and develop, businesses in mobile applications, blockchain/digital assets, SaaS, FinTech and alternative energy solutions, as well as other technologies that address the world’s leading environmental and social concerns. Fernhill supports and pursues ESG initiatives and is Signatory Member of the Crypto Climate Accord (CCA).  

FERN took off in May after the Company reported it had upgraded its listing on OTCMarkets to Pink Current Status and hired senior technology M&A and corporate finance executive, Chris Kern, who has over 25 years of hands-on experience and facilitated over $750 million in transactions. Coupled with the Companys focus areas, Chris has deep industry experience and expertise in the Fintech, SaaS, Crypto/Blockchain, Telecommunications and Internet media industries.   

On July 27 several days after our first report on the Company when the stock was in the $0.02 range FERN announced the Acquisition of PerfectMine, a fully operational turn-key platform that provides optimized operating systems for a wide variety of GPU and CPU mining rigs to improve efficiency as well as remotely monitor and manage them. 

PerfectMine.io, delivered as software as a service (“SaaS”), provides optimized mining operating systems and algorithms, supports multiple cryptocurrencies and tokens such as Ethereum, LiteCoin, Monero and RavenCoin, and has the unique capability to support Multi-Card functionality that can run both Nvidia and AMD GPUs simultaneously, which is not commonly found in the industry. PerfectMine includes robust monitoring and optimization tools to efficiently tune and manage crypto mining rigs to improve hashrate yield and operate at peak efficiency. 

To Find out the inside Scoop on FERN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

FERN

said CEO Marc Lasky said at the time: “We are extremely excited about the acquisition of PerfectMine. We believe it is the perfect first step toward accomplishing our goals. This simple but robust platform allows us to democratize and simplify crypto mining for everyone. Further, it sets the stage for Fernhill to become one of the leading providers of crypto mining tools and resources to help optimize and create green mining solutions for the masses. Acquiring Perfectmine helps Fernhill establish a foundation for making multiple larger acquisitions in the crypto space and moves us closer to our goal of uplisting to Nasdaq.” 

More recently FERN announced an LOI to acquire a groundbreaking digital asset crypto trading platform. In the Company’s continued mission to expand its presence in the cryptocurrency and blockchain industries, it has recently signed an LOI to acquire an institutional digital asset trading company serving banks and hedge funds with technology, strategy development, automated algorithmic trading, best execution, smart order routing, and risk exposure analytics. One of the most compelling features of the target’s technology is that it is directly integrated with over 25 different leading crypto currency exchanges to provide the best execution price for any crypto trading pair, providing seamless liquidity on a global scale. In short, this platform bridges the gap between crypto currencies and the more traditional trading platforms. 

The target acquisition company has developed a proprietary digital asset/crypto trading platform with direct connectivity to the top major cryptocurrency exchanges such as Binance, Coinbase, OKEx, Kraken, and Bittrex to name a few. In addition, the company is based in the United States and has a top-notch executive management team, senior developers and board that come from some of the most prolific financial institutions and corporations in the world. The acquisition is targeted to close on or before November 15, 2021. 

On September 9 FERN announced the appointment of Nathanael Coonrod, as Executive VP of Engineering. Prior to joining Fernhill, Nathanael led multinational engineering and development teams on projects for both established and start-up companies, including Tesla, Roger’s Corp, and FogChain, to name a few. With Fernhill, Nathanael’s duties will include spearheading all product development, technology implementation guidelines and collaborating with all existing and upcoming acquisitions to make sure integration goes smoothly, synergies are created and a technology roadmap is established to support growth. Synergies are exceedingly important in light of Fernhill’s recently announced letter of intent to acquire a digital asset trading platform. 

Fernhill CEO Marc Lasky stated:  “We are thrilled with the appointment of Mr. Coonrod as our EVP of Engineering, Nathanael is a world-class software engineer that has worked on a wide range of mission critical projects with a vast array of companies. He also helped author multiple, issued and pending, patents around blockchain and distributed computing technologies. Having a specialization in blockchain development, crypto mining, and large-scale software development projects, Nathanael has created several cutting-edge technologies and private blockchains that led to multiple successful exits, and as such, I am confident that he is the perfect person to help us take Fernhill to the next level.” 

  We have a Monster Pick Coming. Subscribe Right Now!

FERN continues to move northbound with power in recent trading quickly emerging as an investors favorite and major volume leader regularly topping $5 million in daily trading volume. Microcapdaily first reported on FERN back on July 23 when FERN was in the $0.02 range stating at the time: “FERN is getting noticed by some pretty heavy hitter penny stock players.  FERN took off in May after the Company reported it had upgraded its listing on OTCMarkets to Pink Current Status and hired senior technology M&A and corporate finance executive, Chris Kern, who has over 25 years of hands-on experience and facilitated over $750 million in transactions. FERN has an outstanding looking balance sheet with just $350k in total liabilities. The Company recently announced it is nearing completion of its due diligence on a targeted acquisition in the Cryptocurrency and Blockchain industry signing an LOI to acquire a SaaS based algorithmic crypto mining operating system platform for crypto mining pools and enthusiasts. Since than FERN acquired PerfectMine, a fully operational turn-key platform that provides optimized operating systems for a wide variety of GPU and CPU mining rigs to improve efficiency as well as remotely monitor and manage them. The Company has also signed an LOI to acquire a groundbreaking digital asset crypto trading platform. One of the most compelling features of the target’s technology is that it is directly integrated with over 25 different leading crypto currency exchanges to provide the best execution price for any crypto trading pair, providing seamless liquidity on a global scale. In short, this platform bridges the gap between crypto currencies and the more traditional trading platforms. FERN is trading like a winner with strong new support at every new price level as it continues on a blue sky breakout. We will be updating on FERN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with FERN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in FERN either long or short and we have not been compensated for this article

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Featured

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership

Published

on

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan's proprietary target discovery platform.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable. 

The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. 

Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand: 

Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.

As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.

To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.

Here are a couple of blurbs from the management team

“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”

“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”

What’s retail saying?

As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. 

Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day.  Compared to the ~27M shares traded at the time of writing, that’s a massive shift.

We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

ContraFect Corp (NASDAQ: CFRX): A Low Float Runner

Published

on

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual.

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.

However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.

To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Summary of latest PR on April 26, 2023

ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.

What are retail traders saying?

https://twitter.com/RealWillTopol/status/1651553835801001986?s=20

It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them. 

We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits. 

However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.

About ContraFect Corp (NASDAQ: CFRX)

ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.

We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sasin Tipchai from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.